Literature DB >> 21792479

Angiotensin-II mediates nonmuscle myosin II activation and expression and contributes to human keloid disease progression.

Jennifer E Bond1, Andrew Bergeron, Peter Thurlow, M Angelica Selim, Edith V Bowers, Anna Kuang, Howard Levinson.   

Abstract

Aberrant fibroblast migration in response to fibrogenic peptides plays a significant role in keloid pathogenesis. Angiotensin II (Ang II) is an octapeptide hormone recently implicated as a mediator of organ fibrosis and cutaneous repair. Ang II promotes cell migration but its role in keloid fibroblast phenotypic behavior has not been studied. We investigated Ang II signaling in keloid fibroblast behavior as a potential mechanism of disease. Primary human keloid fibroblasts were stimulated to migrate in the presence of Ang II and Ang II receptor 1 (AT₁), Ang II receptor 2 (AT₂) or nonmuscle myosin II (NMM II) antagonists. Keloid and the surrounding normal dermis were immunostained for NMM IIA, NMM IIB, AT₂ and AT₁ expression. Primary human keloid fibroblasts were stimulated to migrate with Ang II and the increased migration was inhibited by the AT₁ antagonist EMD66684, but not the AT₂ antagonist PD123319. Inhibition of the promigratory motor protein NMM II by addition of the specific NMM II antagonist blebbistatin inhibited Ang II-stimulated migration. Ang II stimulation of NMM II protein expression was prevented by AT₁ blockade but not by AT₂ antagonists. Immunostaining demonstrated increased NMM IIA, NMM IIB and AT₁ expression in keloid fibroblasts compared with scant staining in normal surrounding dermis. AT₂ immunostaining was absent in keloid and normal human dermal fibroblasts. These results indicate that Ang II mediates keloid fibroblast migration and possibly pathogenesis through AT₁ activation and upregulation of NMM II.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21792479      PMCID: PMC3321811          DOI: 10.2119/molmed.2010.00265

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  43 in total

1.  Histopathological differential diagnosis of keloid and hypertrophic scar.

Authors:  Julia Yu-Yun Lee; Chao-Chun Yang; Sheau-Chiou Chao; Tak-Wah Wong
Journal:  Am J Dermatopathol       Date:  2004-10       Impact factor: 1.533

2.  Nonmuscle myosin IIA-dependent force inhibits cell spreading and drives F-actin flow.

Authors:  Yunfei Cai; Nicolas Biais; Gregory Giannone; Monica Tanase; Guoying Jiang; Jake M Hofman; Chris H Wiggins; Pascal Silberzan; Axel Buguin; Benoit Ladoux; Michael P Sheetz
Journal:  Biophys J       Date:  2006-08-18       Impact factor: 4.033

3.  Nonmuscle myosin II moves in new directions.

Authors:  Mary Anne Conti; Robert S Adelstein
Journal:  J Cell Sci       Date:  2008-01-01       Impact factor: 5.285

Review 4.  Angiotensin AT1/AT2 receptors: regulation, signalling and function.

Authors:  Elena Kaschina; Thomas Unger
Journal:  Blood Press       Date:  2003       Impact factor: 2.835

5.  Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease.

Authors:  Begoña Villar-Cheda; Jannette Rodríguez-Pallares; Rita Valenzuela; Ana Muñoz; Maria J Guerra; Ovidiu C Baltatu; Jose L Labandeira-Garcia
Journal:  Eur J Neurosci       Date:  2010-10-21       Impact factor: 3.386

6.  Myosin IIA regulates cell motility and actomyosin-microtubule crosstalk.

Authors:  Sharona Even-Ram; Andrew D Doyle; Mary Anne Conti; Kazue Matsumoto; Robert S Adelstein; Kenneth M Yamada
Journal:  Nat Cell Biol       Date:  2007-02-18       Impact factor: 28.824

7.  Non-peptide angiotensin II receptor antagonists: synthesis and biological activity of a series of novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine derivatives.

Authors:  W W Mederski; D Dorsch; H H Bokel; N Beier; I Lues; P Schelling
Journal:  J Med Chem       Date:  1994-05-27       Impact factor: 7.446

Review 8.  Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism.

Authors:  I Van Liefde; G Vauquelin
Journal:  Mol Cell Endocrinol       Date:  2008-06-21       Impact factor: 4.102

Review 9.  Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases.

Authors:  H Matsubara
Journal:  Circ Res       Date:  1998 Dec 14-28       Impact factor: 17.367

10.  Further evidence for the involvement of MYH9 in the etiology of non-syndromic cleft lip with or without cleft palate.

Authors:  Stefanie Birnbaum; Heiko Reutter; Meinhard Mende; Nilma A de Assis; Amalia Diaz-Lacava; Stefan Herms; Martin Scheer; Carola Lauster; Bert Braumann; Gül Schmidt; Markus Martini; Alexander Hemprich; Simone Pötzsch; Michael Knapp; Markus M Nöthen; Franz-Josef Kramer; Elisabeth Mangold
Journal:  Eur J Oral Sci       Date:  2009-04       Impact factor: 2.612

View more
  8 in total

1.  Angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction.

Authors:  Tosan Ehanire; Licheng Ren; Jennifer Bond; Manuel Medina; George Li; Latif Bashirov; Lei Chen; George Kokosis; Mohamed Ibrahim; Angelica Selim; Gerard C Blobe; Howard Levinson
Journal:  J Mol Med (Berl)       Date:  2014-10-28       Impact factor: 4.599

2.  Nonmuscle Myosin II Activation Regulates Cell Proliferation, Cell Contraction, and Myofibroblast Differentiation in Keloid-Derived Fibroblasts.

Authors:  Ying-Yi Lu; Cheng-Chieh Fang; Chien-Hui Hong; Chieh-Hsin Wu; Yu-Hung Lin; Kee-Lung Chang; Chih-Hung Lee
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-01-14       Impact factor: 4.730

3.  Admixture mapping identifies a locus at 15q21.2-22.3 associated with keloid formation in African Americans.

Authors:  Digna R Velez Edwards; Krystal S Tsosie; Scott M Williams; Todd L Edwards; Shirley B Russell
Journal:  Hum Genet       Date:  2014-10-04       Impact factor: 4.132

4.  A novel immune competent murine hypertrophic scar contracture model: a tool to elucidate disease mechanism and develop new therapies.

Authors:  Mohamed Magdy Ibrahim; Jennifer Bond; Andrew Bergeron; Kyle J Miller; Tosan Ehanire; Carlos Quiles; Elizabeth R Lorden; Manuel A Medina; Mark Fisher; Bruce Klitzman; M Angelica Selim; Kam W Leong; Howard Levinson
Journal:  Wound Repair Regen       Date:  2015-01-08       Impact factor: 3.617

5.  Pre-vascularization Enhances Therapeutic Effects of Human Mesenchymal Stem Cell Sheets in Full Thickness Skin Wound Repair.

Authors:  Lei Chen; Qi Xing; Qiyi Zhai; Mitchell Tahtinen; Fei Zhou; Lili Chen; Yingbin Xu; Shaohai Qi; Feng Zhao
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

6.  Angiotensin-Converting Enzyme Inhibitor, Captopril, Improves Scar Healing in Hypertensive Rats.

Authors:  Eun Young Rha; Jae Won Kim; Jun Hyeok Kim; Gyeol Yoo
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

7.  Dysregulated myosin in Hermansky-Pudlak syndrome lung fibroblasts is associated with increased cell motility.

Authors:  Jewel Imani; Steven P M Bodine; Anthony M Lamattina; Diane D Ma; Shikshya Shrestha; Dawn M Maynard; Kevin Bishop; Arinze Nwokeji; May Christine V Malicdan; Lauren C Testa; Raman Sood; Benjamin Stump; Ivan O Rosas; Mark A Perrella; Robert Handin; Lisa R Young; Bernadette R Gochuico; Souheil El-Chemaly
Journal:  Respir Res       Date:  2022-06-23

8.  Effect of donor non-muscle myosin heavy chain (MYH9) gene polymorphisms on clinically relevant kidney allograft dysfunction.

Authors:  Joanna Pazik; Monika Oldak; Dominika Oziębło; Dominika Dęborska Materkowska; Anna Sadowska; Jacek Malejczyk; Magdalena Durlik
Journal:  BMC Nephrol       Date:  2020-09-01       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.